PURPOSE: To test in a longitudinal follow-up study whether basal glucose metabolism in subjects with a genetic risk of Huntington disease (HD) may influence the onset of manifest symptoms. METHODS: The study group comprised 43 presymptomatic (preHD) subjects carrying the HD mutation. They underwent a (18)F-FDG PET scan and were prospectively followed-up for at least 5 years using the unified HD rating scale to detect clinical changes. Multiple regression analysis included subject's age, CAG mutation size and glucose uptake as variables in a model to predict age at onset. RESULTS: Of the 43 preHD subjects who manifested motor symptoms, suggestive of HD, after 5 years from the PET scan, 26 showed a mean brain glucose uptake below the cut-off of 1.0493 in the caudate, significantly lower than the 17 preHD subjects who remained symptom-free (P < 0.0001). This difference was independent of mutation size. Measurement of brain glucose uptake improved the CAG repeat number and age-based model for predicting age at onset by 37 %. CONCLUSION: A reduced level of glucose metabolism in the brain caudate may represent a predisposing factor that contributes to the age at onset of HD in preHD subjects, in addition to the mutation size.
PURPOSE: To test in a longitudinal follow-up study whether basal glucose metabolism in subjects with a genetic risk of Huntington disease (HD) may influence the onset of manifest symptoms. METHODS: The study group comprised 43 presymptomatic (preHD) subjects carrying the HD mutation. They underwent a (18)F-FDG PET scan and were prospectively followed-up for at least 5 years using the unified HD rating scale to detect clinical changes. Multiple regression analysis included subject's age, CAG mutation size and glucose uptake as variables in a model to predict age at onset. RESULTS: Of the 43 preHD subjects who manifested motor symptoms, suggestive of HD, after 5 years from the PET scan, 26 showed a mean brain glucose uptake below the cut-off of 1.0493 in the caudate, significantly lower than the 17 preHD subjects who remained symptom-free (P < 0.0001). This difference was independent of mutation size. Measurement of brain glucose uptake improved the CAG repeat number and age-based model for predicting age at onset by 37 %. CONCLUSION: A reduced level of glucose metabolism in the brain caudate may represent a predisposing factor that contributes to the age at onset of HD in preHD subjects, in addition to the mutation size.
Authors: J B Penney; A B Young; I Shoulson; S Starosta-Rubenstein; S R Snodgrass; J Sanchez-Ramos; M Ramos-Arroyo; F Gomez; G Penchaszadeh; J Alvir Journal: Mov Disord Date: 1990 Impact factor: 10.338
Authors: Roman Gonitel; Hilary Moffitt; Kirupa Sathasivam; Ben Woodman; Peter J Detloff; Richard L M Faull; Gillian P Bates Journal: Proc Natl Acad Sci U S A Date: 2008-02-25 Impact factor: 11.205
Authors: Adam M Brickman; Monte S Buchsbaum; Lina Shihabuddin; Erin A Hazlett; Joan C Borod; Richard C Mohs Journal: Brain Res Cogn Brain Res Date: 2003-06
Authors: Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout Journal: Lancet Neurol Date: 2009-07-29 Impact factor: 44.182
Authors: Nancy S Wexler; Judith Lorimer; Julie Porter; Fidela Gomez; Carol Moskowitz; Edith Shackell; Karen Marder; Graciela Penchaszadeh; Simone A Roberts; Javier Gayán; Denise Brocklebank; Stacey S Cherny; Lon R Cardon; Jacqueline Gray; Stephen R Dlouhy; Sandra Wiktorski; Marion E Hodes; P Michael Conneally; Jack B Penney; James Gusella; Jang-Ho Cha; Michael Irizarry; Diana Rosas; Steven Hersch; Zane Hollingsworth; Marcy MacDonald; Anne B Young; J Michael Andresen; David E Housman; Margot Mieja De Young; Ernesto Bonilla; Theresa Stillings; Americo Negrette; S Robert Snodgrass; Maria Dolores Martinez-Jaurrieta; Maria A Ramos-Arroyo; Jacqueline Bickham; Juan Sanchez Ramos; Frederick Marshall; Ira Shoulson; Gustavo J Rey; Andrew Feigin; Norman Arnheim; Amarilis Acevedo-Cruz; Leticia Acosta; Jose Alvir; Kenneth Fischbeck; Leslie M Thompson; Angela Young; Leon Dure; Christopher J O'Brien; Jane Paulsen; Adam Brickman; Denise Krch; Shelley Peery; Penelope Hogarth; Donald S Higgins; Bernhard Landwehrmeyer Journal: Proc Natl Acad Sci U S A Date: 2004-03-01 Impact factor: 11.205
Authors: Andreas Matusch; Carsten Saft; David Elmenhorst; Peter H Kraus; Ralf Gold; Hans-Peter Hartung; Andreas Bauer Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-25 Impact factor: 9.236
Authors: Ismini C Mainta; C Tabouret-Viaud; J Horvath; M I Vargas; V Garibotto Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-19 Impact factor: 9.236
Authors: Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi Journal: Nat Rev Neurol Date: 2014-03-11 Impact factor: 42.937
Authors: Frank J A Dennissen; Marta Anglada-Huguet; Astrid Sydow; Eckhard Mandelkow; Eva-Maria Mandelkow Journal: Proc Natl Acad Sci U S A Date: 2016-09-26 Impact factor: 11.205
Authors: Macarena Solís-Maldonado; María Paz Miró; Aníbal I Acuña; Adriana Covarrubias-Pinto; Anitsi Loaiza; Gonzalo Mayorga; Felipe A Beltrán; Carlos Cepeda; Michael S Levine; Ilona I Concha; Luis Federico Bátiz; Mónica A Carrasco; Maite A Castro Journal: CNS Neurosci Ther Date: 2018-04 Impact factor: 5.243